Login
$ZLAB
$23.47 -$1.13 (4.59%) Live

$ZLAB 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

–Zoci 1.6 mg/kg plus atezolizumab showed compelling 1L SCLC data at ESMO: 81.8% confirmed ORR, an estimated 81.9% six-month PFS rate and 9.1% Grade ≥3 zoci-related AEs; advancing toward a global Phase 3 study in 1L SCLC

23 Oct 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 22, 2026, by and among Zai Lab Limited, an exempted company incorporated with limited liability under the laws of the Cayman Islan...

06 Aug 2026 8-K: Results of Operations and Financial Condition

–The Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with significant pipeline catalysts expected in the second half of 2026

17 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 17, 2026, Zai Lab Limited (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Annual Meeting”). Holders of a total of 550,281,867 ordinary shares of the Company, constituting more than one-tenth of all voti...

21 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

On May 18, 2026, the Board of Directors of Zai Lab Limited (the “Company”) determined that Mr. Josh Smiley will cease serving as President and Chief Operating Officer of the Company, effective as of May 18, 2026, and his last day of empl...

07 May 2026 8-K: Results of Operations and Financial Condition

–Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for VYVGART

26 Feb 2026 8-K: Results of Operations and Financial Condition

–Total revenues grew 17% y-o-y to $127.6 million for the fourth quarter of 2025 and 15% y-o-y to $460.2 million for the full-year 2025

06 Nov 2025 8-K: Results of Operations and Financial Condition

–Zocilurtatug pelitecan (zoci, DLL3 ADC) (formerly ZL-1310) data presented at Triple Meeting in October continues to demonstrate first- and best-in-class potential, supporting the recent initiation of the global registrational study in 2...

16 Oct 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

PURSUANT TO ITEM 601(b)(10)(iv) OF REGULATION S-K, THIS EXHIBIT OMITS CERTAIN INFORMATION, IDENTIFIED BY [***], THAT IS NOT MATERIAL AND THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

07 Aug 2025 8-K: Results of Operations and Financial Condition

–Total revenues grew 9% y-o-y to $110.0 million for the second quarter of 2025; reaffirming full-year 2025 revenue guidance of $560 million to $590 million

18 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 18, 2025, Zai Lab Limited (the “Company”) held its 2025 Annual General Meeting of Shareholders (the “Annual Meeting”). Holders of a total of 794,508,200 ordinary shares of the Company, constituting more than one-tenth of all voti...

08 May 2025 8-K: Results of Operations and Financial Condition

–Total revenues grew 22% y-o-y to $106.5 million for the first quarter of 2025; reaffirming full-year 2025 revenue guidance of $560 million to $590 million

27 Feb 2025 8-K: Results of Operations and Financial Condition

–Total revenues grew 66% y-o-y to $109.1 million for the fourth quarter of 2024 and 50% y-o-y to $399.0 million for the full-year 2024; Full-year 2025 revenue guidance of $560 million to $590 million

03 Jan 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

PURSUANT TO ITEM 601(b)(10)(iv) OF REGULATION S-K, THIS EXHIBIT OMITS CERTAIN INFORMATION, IDENTIFIED BY [***], THAT IS NOT MATERIAL AND THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

15 Nov 2024 8-K: Entry into a Material Definitive Agreement; Other Events

Zai Lab Limited, an exempted company incorporated with limited liability under the laws of the Cayman Islands (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for w...

13 Nov 2024 8-K: Other Events

We, our employees, and our contracted third parties are subject to laws and government regulations relating to privacy and data protection that have required us to modify certain of our policies and procedures with respect to the collect...

12 Nov 2024 8-K: Results of Operations and Financial Condition

–Strong growth in net product revenue of 47% y-o-y to reach $101.8 million for the third quarter of 2024

06 Aug 2024 8-K: Results of Operations and Financial Condition

–Net product revenue of $100.1 million for the second quarter of 2024, representing 45% y-o-y growth; 47% y-o-y growth at constant exchange rate (CER)

09 Jul 2024 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

PURSUANT TO ITEM 601(b)(10)(iv) OF REGULATION S-K, THIS EXHIBIT OMITS CERTAIN INFORMATION, IDENTIFIED BY [***], THAT IS NOT MATERIAL AND THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

18 Jun 2024 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The Plan provides for the grant of Awards consisting of, or based on, Shares. The purposes of the Plan are to attract, retain, and reward key Employees and Directors of the Company and its Affiliates, to incentivize them to generate shar...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support